Trial Profile
METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Cancer metastases; Colorectal cancer
- Focus Therapeutic Use
- Acronyms METIMMOX
- 29 Jan 2024 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 20 Jan 2024 Results of circulating Th and NSwM-B cell populations may mediate ICB responsiveness invoked by short-course oxaliplatin-based chemotherapy in patients with abdominal metastases, presented at the 2024 Gastrointestinal Cancers Symposium
- 24 Oct 2023 Results of post hoc analysis exploring the initial two FLOX cycles of alternating short-course FLOX and nivolumab may affect circulating CRP and outcome (progression-free survival; PFS) in first-line treatment of MSS-mCRC, presented at the 48th European Society for Medical Oncology Congress.